Du F, Wang G, Dai Q, Huang J, Li J, Liu C
Biomark Res. 2025; 13(1):35.
PMID: 40012016
PMC: 11866848.
DOI: 10.1186/s40364-025-00748-4.
Zhang M, Li J, Yan K, Zhou H, Mei S, Wang B
Proc Natl Acad Sci U S A. 2025; 122(8):e2422731122.
PMID: 39964714
PMC: 11874271.
DOI: 10.1073/pnas.2422731122.
Chandrasekaran P, Krausz M, Han Y, Mitsuiki N, Gabrysch A, Noltner C
Microbiome. 2025; 13(1):51.
PMID: 39934899
PMC: 11817180.
DOI: 10.1186/s40168-025-02028-7.
Lu Y, Wang Y, Ruan T, Wang Y, Ju L, Zhou M
Front Immunol. 2025; 16:1536020.
PMID: 39917294
PMC: 11798928.
DOI: 10.3389/fimmu.2025.1536020.
Wang S, Wang H
Transl Cancer Res. 2025; 13(12):7002-7014.
PMID: 39816545
PMC: 11729759.
DOI: 10.21037/tcr-24-2150.
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.
Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A
Int J Mol Sci. 2025; 26(1.
PMID: 39795946
PMC: 11719825.
DOI: 10.3390/ijms26010088.
The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.
Li G, Che X, Wang S, Liu D, Xie D, Jiang B
Ann Med. 2025; 57(1):2447403.
PMID: 39757995
PMC: 11705547.
DOI: 10.1080/07853890.2024.2447403.
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.
Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F
Med Oncol. 2024; 42(1):36.
PMID: 39719469
DOI: 10.1007/s12032-024-02588-y.
The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives.
Marchetti M, Ferrari J, Vezzaro T, Masatti L, Tasca G, Maggino T
J Clin Med. 2024; 13(23).
PMID: 39685500
PMC: 11642574.
DOI: 10.3390/jcm13237041.
Congenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans.
Allard-Chamard H, Hillier K, Ramseier M, Bertocchi A, Kaneko N, Premo K
Blood Adv. 2024; 9(3):520-532.
PMID: 39626280
PMC: 11814514.
DOI: 10.1182/bloodadvances.2024013267.
Immuno-oncologic profiling by stage-dependent transcriptome and proteome analyses of spontaneously regressing canine cutaneous histiocytoma.
Loriani Fard A, Haake A, Jovanovic V, Andreotti S, Hummel M, Hempel B
PeerJ. 2024; 12:e18444.
PMID: 39619201
PMC: 11606323.
DOI: 10.7717/peerj.18444.
Extraordinary diversity of the CD28/CTLA4 family across jawed vertebrates.
Quiniou S, Clark T, Bengten E, Rast J, Ohta Y, Flajnik M
Front Immunol. 2024; 15:1501934.
PMID: 39606244
PMC: 11599192.
DOI: 10.3389/fimmu.2024.1501934.
Ferroptosis contributes to immunosuppression.
He N, Yuan D, Luo M, Xu Q, Wen Z, Wang Z
Front Med. 2024; 19(1):1-22.
PMID: 39560919
DOI: 10.1007/s11684-024-1080-8.
Expression of Immune Checkpoint Regulator Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death Protein Ligand 1 (PD-L1) in Invasive Ductal Carcinoma Breast.
Diwaker P, Jha T, Gogoi P, Arora V, Ansari M, Kaur N
Indian J Surg Oncol. 2024; 15(4):713-720.
PMID: 39555338
PMC: 11564441.
DOI: 10.1007/s13193-024-01977-z.
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.
Shi X, Cheng X, Jiang A, Shi W, Zhu L, Mou W
Adv Sci (Weinh). 2024; 11(47):e2403423.
PMID: 39509319
PMC: 11653663.
DOI: 10.1002/advs.202403423.
Flotillin-2 dampens T cell antigen sensitivity and functionality.
Moon S, Zhao F, Uddin M, Tucker C, Karmaus P, Fessler M
JCI Insight. 2024; 9(24).
PMID: 39499901
PMC: 11665568.
DOI: 10.1172/jci.insight.182328.
CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner.
Lo J, Schroeder J, Roberts L, Mohamed R, Cozzetto D, Beattie G
Nat Commun. 2024; 15(1):9520.
PMID: 39496592
PMC: 11535242.
DOI: 10.1038/s41467-024-51719-6.
Application of novel CAR technologies to improve treatment of autoimmune disease.
Cheever A, Kang C, ONeill K, Weber K
Front Immunol. 2024; 15:1465191.
PMID: 39445021
PMC: 11496059.
DOI: 10.3389/fimmu.2024.1465191.
Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.
Giorgioni L, Ambrosone A, Cometa M, Salvati A, Nistico R, Magrelli A
Int J Mol Sci. 2024; 25(19).
PMID: 39408696
PMC: 11476879.
DOI: 10.3390/ijms251910365.
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
Liu Y, Zhou F, Ali H, Lathia J, Chen P
Cell Mol Immunol. 2024; 21(12):1354-1375.
PMID: 39406966
PMC: 11607068.
DOI: 10.1038/s41423-024-01226-x.